Université de Liège (ULG)
Welcome,         Profile    Billing    Logout  
 6 Trials 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Beguin, Yves
TRACE, NCT04832607 / 2018-000853-29: Multivirus-specific T-cell Transfer Post SCT vs AdV, CMV and EBV Infections

Recruiting
3
149
Europe
Multivirus (CMV, EBV, AdV)-specific T cells
Prof. Tobias Feuchtinger, European Commission, Simbec-Orion Group Ltd, Merthyr Tydfil, UK, Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany, Leiden University Medical Center, LUMC, Leiden, The Netherlands, Centre Hospitalier Universitaire de Nancy, CHU, Vandoeuvre-Lès-Nancy, France, Ghent University Hospital, UZG, Ghent, Belgium, Ospedale Pediatrico Bambino Gesù, OPBG, Rome, Italy, Newcastle University, UNEW, Newcastle, UK, Vall d'Hebron Institute of Oncology (VHIO) and Banc de Sang I Teixits (BST), Barcelona, Spain
AdV Infection, EBV Infection, CMV Infection, Stem Cell Transplant Complications
06/24
12/24
Predictor2, NCT03887156: Evaluation of a Donor Testing Kit for the Prediction of AGVHD in Patient Receiving a Peripheral Blood Stem Cell Allograft

Recruiting
2/3
227
Europe
Ex vivo capacities of CD4neg INkT expansion of the peripheral blood donor with the Predictor test
Assistance Publique - Hôpitaux de Paris, SATT, SNC Graft Versus Host Disease, Imagine Institute, Axonal-Biostatem, CERBA laboratory
Acute Myeloid Leukemia in Remission, Lymphoma in Remission, Non-progressive Myeloproliferative Syndrome, Myelodysplasia With Stable Blasts is Cell Number and < 10% of Blastocysts, Acute Leukemia Biphenotypic in Remission, Acute Lymphoblastic Leukemia
03/23
03/23
NCT03083574: Extracorporeal Photopheresis Using Theraflex ECP™ for Patients With Refractory Chronic Graft Versus Host Disease (cGVHD)

Recruiting
2
100
Europe
Photopheresis Theraflex ECP™
Jules Bordet Institute, Macopharma, Belgian Hematological Society
Refractory Chronic Graft Versus Host Disease (cGVHD)
09/22
09/23
NCT00603330: Mesenchymal Stem Cell Infusion as Treatment for Steroid-Resistant Acute Graft Versus Host Disease (GVHD) or Poor Graft Function

Recruiting
2
100
Europe
Mesenchymal stem cells
University of Liege, KU Leuven, Maastricht University Medical Center, Ziekenhuis Netwerk Antwerpen (ZNA), University Hospital, Antwerp, University Hospital, Ghent, AZ-VUB, AZ Sint-Jan AV, Cliniques universitaires Saint-Luc- Université Catholique de Louvain, University Hospital of Mont-Godinne, Jolimont Hospital Haine Saint Paul, Queen Fabiola Children's University Hospital
Graft-versus-host Disease, Poor Graft Function, Low Donor T-cell Chimerism
08/24
08/24
NCT04445454: Mesenchymal Stromal Cell Therapy for Severe Covid-19 Infection

Recruiting
1/2
20
Europe
Mesenchymal stromal cells, MSC
University of Liege
Coronavirus Infection
09/24
09/24
CYCLE-1, NCT04167696: Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02

Recruiting
1
27
Europe, US
CYAD-02, ENDOXAN, cyclophosphamide, Fludara, fludarabine
Celyad Oncology SA
Acute Myeloid Leukemia, Myelodysplastic Syndrome
12/21
02/35

Download Options